Sandalwood giant can smell big dollars in warts more

ViroXis Corporation Announces expanded board of directors and advisors more

ITClamp Hemorrhage Control System from Innovative Trauma Care more

ViroXis Corporation Initiates Phase II Clinical Trial of Novel Botanical Topical Treatment for HPV Skin Warts more

Vidacare Corp. aims to ease that pain with the OnControl Bone Marrow System. The Bronze winner of The Wall Street Journal's Technology Innovation Awards, and winner of the Medical-Devices category, the product allows doctors to more quickly and precisely take samples from inside the bone more

DNAtrix, Inc., the Houston-based biotechnology company developing targeted adenovirus-based oncolytic virus products, announced today a merger with VectorLogics, Inc. more

Innovative Trauma Care (ITC) has received regulatory approval from Health Canada for commercial sale of its first product, the IT Clamp™ more

BiO2 Medical, Inc and R&D and manufacturing operations in Golden, Colorado, has recently secured $12M in Series C funding more

ENTrigue Surgical Announces Sinus Surgery Collaboration with fiagon GmbH more

Soluble Therapeutics, Inc. Awarded ~$1MM NIH Grant for Continued Development of the HSC Technology for Protein Formulation more

Vidacare Corporation Creates New Medical Director of Clinical Affairs Position for Intraosseous Vascular Access Division more

BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication more

NMP Neuwirth Medical Products GmbH signs an exclusive distribution partnership for the Ventera, MediENT, ENTact, Synaero, and SerpENT in Germany

ENTrigue Surgical participates in the first Global Update on FESS, The Sinuses, and The Nose in Vienna, Austria

BiO2 Medical Announces First in Man Clinical Study more

BiO2 Medical Secures Series B Round Funding more

Study Finds Intraosseous Infusion is Equivalent to Intravenous Infusion During Therapeutic Hypothermia.

The results of a study conducted by Vidacare Corporation comparing whether Intraosseous (IO) vascular access may be used to infuse chilled saline as effectively as peripheral intravenous (IV) access to achieve therapeutic hypothermia found no statistical difference between the two routes. The findings were announced on January 12 at an oral presentation at the National Association of EMS Physicians 2012 Annual Meeting by Dr. Larry J. Miller and the Science and Clinical team from Vidacare Corporation, makers of the EZ-IO Intraosseous Infusion System.

The study [Abstract#2], “Infusing Chilled Saline Through the Intraosseous Route is Equivalent to Infusion Through the Intravenous Route in Reducing the Core Temperature in Swine,” investigated whether Intraosseous (IO) vascular access may be effectively used to infuse chilled saline to achieve Therapeutic hypothermia (TH) as an alternative to peripheral intravenous (IV) access. The study found that IO and IV temperature reductions were statistically equivalent, and concluded no clinical or statistical difference between IV and IO when comparing the two routes for infusion of chilled saline for therapeutic hypothermia.

The research study used the EZ-IO Intraosseous Infusion System – the first battery-powered device to establish immediate vascular access and the only IO device which is FDA cleared for humeral insertion.  The EZ-IO is used by 90 percent of US advanced life support ambulances and over half of US Emergency Departments, as well as the US Military.

Established in 2001, Vidacare Corporation is the developer of a broad technology platform that is defining the field of intraosseous medicine. Current products include the EZ-IO Intraosseous Infusion System, the OnControl™ Bone Marrow System and the OnControl™Bone Access System, and applications include vascular access, emergency and disaster medicine, oncology and spinal surgery. Vidacare’s focus on enhancing clinical efficacy, patient safety and comfort, and reducing complications and their associated costs, has resulted in its devices becoming the recognized technology standard. Privately held, the company is based in San Antonio, Texas,and its products are marketed in over 50 countries worldwide. back

Vidacare Corporation to Sponsor 2012 British Journal of Nursing Haematology Award Category more